PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

Company Overview

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Key Stats

• Today's Range: $1.24 to $1.32
• 50-Day Range: $1.14 to $1.60
• 52-Week Range: $0.81 to $1.84
• Volume: 810,415 shs
• Average Volume: 2.74 million shs
• Market Capitalization: $69.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

PMV Pharmaceuticals Stock Analysis - MarketRank™

PMV Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 349th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

PMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

PMV Pharmaceuticals has a consensus price target of $5.50, representing about 319.8% upside from its current price of $1.31.

Amount of Analyst Coverage

PMV Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.06) to ($1.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PMV Pharmaceuticals is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PMV Pharmaceuticals is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PMV Pharmaceuticals has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.81% of the float of PMV Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

PMV Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PMV Pharmaceuticals has recently increased by 0.61%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PMV Pharmaceuticals does not currently pay a dividend.

Dividend Growth

PMV Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.81% of the float of PMV Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

PMV Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PMV Pharmaceuticals has recently increased by 0.61%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.64

News Sentiment

PMV Pharmaceuticals has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

4 people have searched for PMVP on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

1 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PMV Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,021,505.00 in company stock.

Percentage Held by Insiders

Only 7.57% of the stock of PMV Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PMVP Stock Analysis - Frequently Asked Questions

How have PMVP shares performed this year?

PMV Pharmaceuticals' stock was trading at $1.51 at the beginning of 2025. Since then, PMVP stock has decreased by 13.2% and is now trading at $1.31.

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.02.

When did PMV Pharmaceuticals IPO?

PMV Pharmaceuticals (PMVP) raised $126 million in an IPO on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' top institutional shareholders include BML Capital Management LLC (9.62%), Acadian Asset Management LLC (3.98%), Stonepine Capital Management LLC (1.60%) and Peapod Lane Capital LLC (0.87%). Insiders that own company stock include Orbimed Advisors Llc, David Henry Mack, Robert Ticktin, Deepika Jalota and Michael Carulli.
View institutional ownership trends.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/21/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMVP
• CIK: 1699382
• Web: www.pmvpharma.com
• Phone: 609-642-6670
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for PMV Pharmaceuticals: $5.50
• High Price Target: $6.00
• Low Price Target: $5.00
• Potential Upside/Downside: +319.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.94%
• Return on Assets: -43.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.52
• Quick Ratio: 12.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.40 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 52,990,000
• Free Float: 48,980,000
• Market Cap: $69.42 million
• Optionable: Optionable
• Beta: 1.52